T1	PROC 40 58	tratamiento tópico
#1	AnnotatorNotes T1	C0001566; Administration, Topical; Therapeutic or Preventive Procedure
T2	DISO 65 76	fisura anal
#2	AnnotatorNotes T2	C0016167; Anal Fissure; Disease or Syndrome
T3	PROC 277 289	randomizados
#3	AnnotatorNotes T3	C0034656; Randomization; Research Activity
T4	PROC 140 157	aplicación tópica
#4	AnnotatorNotes T4	C0683174; topical application; Therapeutic or Preventive Procedure
T5	PROC 187 198	tratamiento
#5	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	DISO 206 220	fisuras anales
#6	AnnotatorNotes T6	C0016167; Anal Fissure; Disease or Syndrome
T7	CHEM 161 180	gliceril trinitrato
#7	AnnotatorNotes T7	C0017887; Nitroglycerin; Organic Chemical · Pharmacologic Substance
T8	CHEM 301 320	gliceril trinitrato
#8	AnnotatorNotes T8	C0017887; Nitroglycerin; Organic Chemical · Pharmacologic Substance
T9	DISO 530 538	síntomas
#9	AnnotatorNotes T9	C1457887; Symptoms; Sign or Symptom
T10	PROC 552 563	tratamiento
#10	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	PROC 608 628	valoración del dolor
#11	AnnotatorNotes T11	C0030198; Pain Measurement; Diagnostic Procedure
T12	PROC 630 641	Seguimiento
#12	AnnotatorNotes T12	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T13	PROC 668 695	controlar la sintomatología
#13	AnnotatorNotes T13	C1274136; Symptom control (regime/therapy); Therapeutic or Preventive Procedure
T14	DISO 681 695	sintomatología
#14	AnnotatorNotes T14	C3540840; Sign or Symptom; Finding
T15	DISO 723 739	efectos adversos
#15	AnnotatorNotes T15	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T16	PROC 958 969	tratamiento
#16	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	PROC 1023 1046	intervención quirúrgica
#17	AnnotatorNotes T17	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T18	CHEM 1311 1330	gliceril trinitrato
#18	AnnotatorNotes T18	C0017887; Nitroglycerin; Organic Chemical · Pharmacologic Substance
T19	DISO 1104 1111	cefalea
#19	AnnotatorNotes T19	C0018681; Headache; Sign or Symptom
T20	DISO 1119 1136	rubicundez facial
#20	AnnotatorNotes T20	C0016382; Flushing; Sign or Symptom
T21	DISO 1191 1198	cefalea
#21	AnnotatorNotes T21	C0018681; Headache; Sign or Symptom
T22	PROC 1290 1307	aplicación tópica
#22	AnnotatorNotes T22	C0683174; topical application; Therapeutic or Preventive Procedure
T23	DISO 1346 1360	fisuras anales
#23	AnnotatorNotes T23	C0016167; Anal Fissure; Disease or Syndrome
T24	CHEM 1159 1162	GTN
#24	AnnotatorNotes T24	C0017887; Nitroglycerin; Organic Chemical · Pharmacologic Substance
T25	ANAT 72 76	anal
#25	AnnotatorNotes T25	C0003461; Anus; Body Part, Organ, or Organ Component | C1278927; Entire anus; Body Part, Organ, or Organ Component
T26	ANAT 214 220	anales
#26	AnnotatorNotes T26	C0003461; Anus; Body Part, Organ, or Organ Component | C1278927; Entire anus; Body Part, Organ, or Organ Component
T27	DISO 579 588	patología
#27	AnnotatorNotes T27	C0677042; Pathology processes; Pathologic Function
T28	DISO 623 628	dolor
#28	AnnotatorNotes T28	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T29	DISO 799 804	dolor
#29	AnnotatorNotes T29	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T30	DISO 879 885	fisura
#30	AnnotatorNotes T30	C0016167; Anal Fissure; Disease or Syndrome
T31	PROC 974 985	tratamiento
#31	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	ANAT 1130 1136	facial
#32	AnnotatorNotes T32	C1281591; Entire face; Body Location or Region | C0015450; Face; Body Location or Region
T33	ANAT 1354 1360	anales
#33	AnnotatorNotes T33	C0003461; Anus; Body Part, Organ, or Organ Component | C1278927; Entire anus; Body Part, Organ, or Organ Component
T34	CHEM 14 33	gliceril trinitrato
#34	AnnotatorNotes T34	C0017887; Nitroglycerin; Organic Chemical · Pharmacologic Substance
T35	Route 52 58	tópico
#35	AnnotatorNotes T35	C1522168; Topical Route of Drug Administration; Functional Concept
T36	Route 151 157	tópica
#36	AnnotatorNotes T36	C1522168; Topical Route of Drug Administration; Functional Concept
T37	LIVB 223 232	Pacientes
#37	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	LIVB 262 271	pacientes
#38	AnnotatorNotes T38	C0030705; Patients; Patient or Disabled Group
T39	Dose 321 328	al 0,2%
T40	Form 329 332	gel
#39	AnnotatorNotes T40	C0017243; Gel; Biomedical or Dental Material
T41	Frequency 333 349	dos veces al día
T42	Duration 359 381	un mínimo de 6 semanas
T43	LIVB 393 402	pacientes
#40	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	LIVB 425 432	mujeres
#41	AnnotatorNotes T44	C0043210; Woman; Population Group
T46	LIVB 482 491	pacientes
#42	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	PHYS 709 717	curación
#43	AnnotatorNotes T47	C2004454; Recovery - healing process; Organism Function
T48	PHYS 864 872	curación
#44	AnnotatorNotes T48	C2004454; Recovery - healing process; Organism Function
T49	Duration 888 901	las 4 semanas
T50	LIVB 919 928	pacientes
#45	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Duration 941 954	las 9 semanas
T52	LIVB 1083 1092	pacientes
#46	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	LIVB 1178 1187	pacientes
#47	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	Route 1301 1307	tópica
#48	AnnotatorNotes T54	C1522168; Topical Route of Drug Administration; Functional Concept
T55	Dose 1331 1338	al 0,2%
T56	LIVB 412 419	varones
#49	AnnotatorNotes T56	C0025266; Male population group; Population Group
T45	Age 455 473	entre 20 y 78 años
T57	Duration 644 661	4, 8 y 12 semanas
T58	DISO 757 765	recidiva
#50	AnnotatorNotes T58	C2825055; Recurrence (disease attribute); Pathologic Function
A1	Status T27 History_of
R1	Has_Route_or_Mode Arg1:T34 Arg2:T35	
R2	Used_for Arg1:T34 Arg2:T1	
R3	Location_of Arg1:T25 Arg2:T2	
R4	Has_Route_or_Mode Arg1:T7 Arg2:T36	
R5	Used_for Arg1:T7 Arg2:T4	
R6	Used_for Arg1:T7 Arg2:T5	
R7	Location_of Arg1:T26 Arg2:T6	
R8	Experiences Arg1:T38 Arg2:T8	
R9	Experiences Arg1:T37 Arg2:T8	
R10	Before Arg1:T3 Arg2:T8	
R11	Has_Dose_or_Strength Arg1:T8 Arg2:T39	
R12	Has_Drug_Form Arg1:T8 Arg2:T40	
R13	Has_Frequency Arg1:T8 Arg2:T41	
R14	Has_Duration_or_Interval Arg1:T8 Arg2:T42	
R15	Has_Age Arg1:T44 Arg2:T45	
R16	Has_Age Arg1:T56 Arg2:T45	
R17	Has_Age Arg1:T43 Arg2:T45	
R18	Experiences Arg1:T46 Arg2:T9	
T59	CONC 565 577	localización
#51	AnnotatorNotes T59	C0475264; localization; Functional Concept
T60	CONC 540 563	duración de tratamiento
#52	AnnotatorNotes T60	C0444921; Duration of treatment; Temporal Concept
R19	Experiences Arg1:T46 Arg2:T27	
R20	Overlap Arg1:T9 Arg2:T27	
R21	Experiences Arg1:T46 Arg2:T10	
R23	Experiences Arg1:T46 Arg2:T28	
R24	Experiences Arg1:T46 Arg2:T11	
R25	Overlap Arg1:T12 Arg2:T57	
T61	Observation 783 804	disminución del dolor
#53	AnnotatorNotes T61	C5230944; Sensation of pain reduced; Finding
R31	Before Arg1:T29 Arg2:T61	
R32	Overlap Arg1:T48 Arg2:T49	
R33	Experiences Arg1:T50 Arg2:T61	
R34	Experiences Arg1:T50 Arg2:T29	
R35	Experiences Arg1:T50 Arg2:T48	
R36	Experiences Arg1:T50 Arg2:T30	
R37	Experiences Arg1:T50 Arg2:T16	
R38	Has_Duration_or_Interval Arg1:T16 Arg2:T51	
R39	Has_Duration_or_Interval Arg1:T16 Arg2:T49	
R40	Overlap Arg1:T48 Arg2:T51	
T62	Observation 974 991	tratamiento falló
#54	AnnotatorNotes T62	C0162643; treatment failure; Finding
R41	Before Arg1:T31 Arg2:T62	
R42	Before Arg1:T62 Arg2:T17	
R43	Before Arg1:T31 Arg2:T17	
R44	Experiences Arg1:T52 Arg2:T19	
R45	Experiences Arg1:T52 Arg2:T20	
R46	Location_of Arg1:T32 Arg2:T20	
R47	After Arg1:T20 Arg2:T24	
R48	After Arg1:T19 Arg2:T24	
T63	Quantifier_or_Qualifier 1112 1116	leve
#55	AnnotatorNotes T63	C2945599; Mild (qualifier value); Qualitative Concept
R49	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T63	
R50	Before Arg1:T24 Arg2:T21	
R51	Experiences Arg1:T53 Arg2:T21	
R52	Experiences Arg1:T53 Arg2:T24	
T64	Quantifier_or_Qualifier 1203 1210	intensa
#56	AnnotatorNotes T64	C0522510; With intensity; Qualitative Concept
R53	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T64	
T65	Observation 1274 1283	beneficio
R54	Causes Arg1:T22 Arg2:T65	
R55	Has_Route_or_Mode Arg1:T18 Arg2:T54	
R56	Used_for Arg1:T18 Arg2:T22	
R57	Has_Dose_or_Strength Arg1:T18 Arg2:T55	
R58	Location_of Arg1:T33 Arg2:T23	
R22	Overlap Arg1:T13 Arg2:T57	
R26	Overlap Arg1:T47 Arg2:T57	
R27	Overlap Arg1:T15 Arg2:T57	
R28	Overlap Arg1:T58 Arg2:T57	
R29	Before Arg1:T30 Arg2:T48	
R30	Overlap Arg1:T29 Arg2:T30	
#57	AnnotatorNotes T65	C4049461; Unexpected beneficial therapeutic response; Finding (?)
A2	Experiencer T37 Patient
A3	Experiencer T38 Patient
A4	Experiencer T43 Patient
A5	Experiencer T56 Patient
A6	Experiencer T44 Patient
A7	Experiencer T46 Patient
A8	Experiencer T50 Patient
A9	Experiencer T52 Patient
A10	Experiencer T53 Patient
